Proton pump inhibitor use and the risk of hepatocellular
carcinoma: A systematic review of pharmacoepidemiological data

J 2021

Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

SINGH, A.; Mohammad Salman HUSSAIN; R. JHA; A. S. JAYRAJ; Miloslav KLUGAR et. al.

Základní údaje

Originální název

Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

Autoři

SINGH, A.; Mohammad Salman HUSSAIN (356 Indie, domácí); R. JHA; A. S. JAYRAJ; Miloslav KLUGAR (203 Česká republika, domácí) a B. ANTONY (garant)

Vydání

JOURNAL OF EVIDENCE BASED MEDICINE, HOBOKEN, WILEY, 2021, 1756-5383

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.224

Kód RIV

RIV/00216224:14110/21:00123257

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/jebm.12456

UT WoS

000706758800001

EID Scopus

2-s2.0-85116877084

Klíčová slova anglicky

hepatocellular carcinoma; meta-analysis; pharmacoepidemiological study; proton pump inhibitors; real-world evidence; systematic review

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 2. 2022 11:18, Mgr. Tereza Miškechová

Anotace

V originále

Proton pump inhibitors (PPIs) were first introduced in the market in the 1980s and are used as an over-the-counter (OTC) drug for acid-related diseases of the gastrointestinal tract. (1) Over the years, both prescription and non-prescription use of PPIs has grown exponentially, and they are now among the most widely used class of drugs globally. (2) PPIs are generally intended for short-term use and are rarely required beyond four to eight weeks; however, in real-world practice, their duration of use often extends beyond recommended guidelines. Hepatocellular carcinoma (HCC), a primary liver cancer, is a heterogeneous disease with multiple variables that differ by geography and presence or absence of prognostic factors such as NAFLD and cirrhosis. Preclinical studies have found PPIs-induced acid suppression to be associated with disease progression in hepatic diseases such as alcoholic liver disease, NAFLD, non-alcoholic steatohepatitis, and liver tumors. Similarly, population-based studies have also found an association of PPIs use with the risk of acute liver injury. (3) Nevertheless, many recent pharmacoepidemiologic studies using real-world databases to evaluate the association between PPIs and the risk of HCC show divergent results. (4-6) Thus, a systematic review was conducted to identify all the published articles and to determine the effect of PPI on the risk of HCC based on real-world data studies.

Citovat

SINGH, A.; Mohammad Salman HUSSAIN; R. JHA; A. S. JAYRAJ; Miloslav KLUGAR a B. ANTONY. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. JOURNAL OF EVIDENCE BASED MEDICINE. HOBOKEN: WILEY, 2021, roč. 14, č. 4, s. 278-280. ISSN 1756-5383. Dostupné z: https://dx.doi.org/10.1111/jebm.12456.

@article{1809821,
   author = {Singh, A. and Hussain, Mohammad Salman and Jha, R. and Jayraj, A. S. and Klugar, Miloslav and Antony, B.},
   article_location = {HOBOKEN},
   article_number = {4},
   doi = {http://dx.doi.org/10.1111/jebm.12456},
   keywords = {hepatocellular carcinoma; meta-analysis; pharmacoepidemiological study; proton pump inhibitors; real-world evidence; systematic review},
   language = {eng},
   issn = {1756-5383},
   journal = {JOURNAL OF EVIDENCE BASED MEDICINE},
   title = {Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data},
   url = {https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456},
   volume = {14},
   year = {2021}
}

TY  - JOUR
ID  - 1809821
AU  - Singh, A. - Hussain, Mohammad Salman - Jha, R. - Jayraj, A. S. - Klugar, Miloslav - Antony, B.
PY  - 2021
TI  - Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data
JF  - JOURNAL OF EVIDENCE BASED MEDICINE
VL  - 14
IS  - 4
SP  - 278-280
EP  - 278-280
PB  - WILEY
SN  - 17565383
KW  - hepatocellular carcinoma
KW  - meta-analysis
KW  - pharmacoepidemiological study
KW  - proton pump inhibitors
KW  - real-world evidence
KW  - systematic review
UR  - https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456
N2  - Proton pump inhibitors (PPIs) were first introduced in the market in the 1980s and are used as an over-the-counter (OTC) drug for acid-related diseases of the gastrointestinal tract. (1) Over the years, both prescription and non-prescription use of PPIs has grown exponentially, and they are now among the most widely used class of drugs globally. (2) PPIs are generally intended for short-term use and are rarely required beyond four to eight weeks; however, in real-world practice, their duration of use often extends beyond recommended guidelines. Hepatocellular carcinoma (HCC), a primary liver cancer, is a heterogeneous disease with multiple variables that differ by geography and presence or absence of prognostic factors such as NAFLD and cirrhosis. Preclinical studies have found PPIs-induced acid suppression to be associated with disease progression in hepatic diseases such as alcoholic liver disease, NAFLD, non-alcoholic steatohepatitis, and liver tumors. Similarly, population-based studies have also found an association of PPIs use with the risk of acute liver injury. (3) Nevertheless, many recent pharmacoepidemiologic studies using real-world databases to evaluate the association between PPIs and the risk of HCC show divergent results. (4-6) Thus, a systematic review was conducted to identify all the published articles and to determine the effect of PPI on the risk of HCC based on real-world data studies.
ER  -

SINGH, A.; Mohammad Salman HUSSAIN; R. JHA; A. S. JAYRAJ; Miloslav KLUGAR a B. ANTONY. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. \textit{JOURNAL OF EVIDENCE BASED MEDICINE}. HOBOKEN: WILEY, 2021, roč.~14, č.~4, s.~278-280. ISSN~1756-5383. Dostupné z: https://dx.doi.org/10.1111/jebm.12456.

Přehled o publikaci